{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:23:32Z","timestamp":1789676612817,"version":"4.0.1"},"reference-count":60,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"EK\u00d6P-24-3 University Research Scholarship Program of the Ministry for Culture and Innovation"},{"name":"J\u00e1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD) is a common metabolic liver disease linked to obesity and diabetes. This study aimed to assess whether serum GOT and GPT can predict NAFLD early in at-risk individuals. A retrospective cohort study was conducted using hospital records from the University of Debrecen (2012\u20132022), including 4886 NAFLD-free individuals at baseline. NAFLD incidence was tracked using ICD-10 codes, with transaminase levels (GOT and GPT) and key metabolic comorbidities analyzed as predictors in a longitudinal design. Survival analysis included Fleming\u2013Harrington tests, Kaplan\u2013Meier, and Nelson\u2013Aalen estimators as well as restricted mean survival time. The Royston\u2013Parmar flexible parametric model was used to assess the time-dependent effects of GOT, GPT, and metabolic risk factors on NAFLD incidence. An elevated GOT was significantly associated with an increased NAFLD hazard (HR = 2.71, 95% CI: 1.31\u20135.58), as was an elevated GPT (HR = 2.21, 95% CI: 1.09\u20134.43). Disorders of lipid metabolism showed the strongest association (HR = 3.29, 95% CI: 1.51\u20137.25). Elevated GOT and GPT levels, in combination with demographic and clinical factors, may serve as valuable prognostic biomarkers for NAFLD progression, underscoring the importance of routine liver enzyme monitoring and comprehensive metabolic management to improve long-term patient outcomes.<\/jats:p>","DOI":"10.3390\/ijms26115057","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T20:26:50Z","timestamp":1748204810000},"page":"5057","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Flexible Parametric Survival Modeling of Transaminases as Predictive Biomarkers for Non-Alcoholic Fatty Liver Disease: A Retrospective Longitudinal Study (2012\u20132022)"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0593-0188","authenticated-orcid":false,"given":"Amr Sayed","family":"Ghanem","sequence":"first","affiliation":[{"name":"Department of Health Informatics, Faculty of Health Sciences, University of Debrecen, 4028 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6811-0113","authenticated-orcid":false,"given":"\u00c1gnes","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Department of Integrative Health Sciences, Faculty of Health Sciences, University of Debrecen, 4028 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0620-7753","authenticated-orcid":false,"given":"P\u00e9ter","family":"Tak\u00e1cs","sequence":"additional","affiliation":[{"name":"Department of Health Informatics, Faculty of Health Sciences, University of Debrecen, 4028 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7022-5932","authenticated-orcid":false,"given":"Battamir","family":"Ulambayar","sequence":"additional","affiliation":[{"name":"Department of Health Informatics, Faculty of Health Sciences, University of Debrecen, 4028 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5066-0646","authenticated-orcid":false,"given":"Marianna","family":"M\u00f3r\u00e9","sequence":"additional","affiliation":[{"name":"Institute of Social and Sociological Sciences, Faculty of Health Sciences, University of Debrecen, 4400 Ny\u00edregyh\u00e1za, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0554-7350","authenticated-orcid":false,"given":"Attila Csaba","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Health Informatics, Faculty of Health Sciences, University of Debrecen, 4028 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"ref_1","unstructured":"(2025, January 26). Definition & Facts of NAFLD & NASH\u2014NIDDK, Available online: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/definition-facts."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1007\/s00261-024-04285-w","article-title":"Differences in the Prevalence of NAFLD, MAFLD, and MASLD According to Changes in the Nomenclature in a Health Check-up Using MRI-Derived Proton Density Fat Fraction","volume":"49","author":"Park","year":"2024","journal-title":"Abdom. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the Diagnosis and Management of Metabolic Associated Fatty Liver Disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Takahashi, Y., Dungubat, E., Kusano, H., and Fukusato, T. (2023). Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors. Biomedicines, 11.","DOI":"10.3390\/biomedicines11102761"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease\u2014Meta-analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic Fatty Liver Disease 2020: The State of the Disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_10","unstructured":"(2024, June 27). Global Burden of Disease (GBD). Available online: https:\/\/www.healthdata.org\/research-analysis\/gbd."},{"key":"ref_11","first-page":"884","article-title":"Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, and Type 2 Diabetes Mellitus: Where Do We Stand Today?","volume":"19","author":"Mitrovic","year":"2023","journal-title":"Arch. Med. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Suwa\u0142a, S., and Junik, R. (2024). Assessment of the Liver Steatosis and Fibrosis Risk in Metabolic Syndrome and Its Individual Components, Considering the Varying Definitions Used in Clinical Practice throughout Time: A Retrospective Cross-Sectional Study. Biomedicines, 12.","DOI":"10.3390\/biomedicines12081739"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11883-022-01028-4","article-title":"Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease","volume":"24","author":"Martin","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus","volume":"22","author":"Dharmalingam","year":"2018","journal-title":"Indian. J. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zeng, P., Cai, X., Yu, X., and Gong, L. (2023). Markers of Insulin Resistance Associated with Non-Alcoholic Fatty Liver Disease in Non-Diabetic Population. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-47269-4"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Koo, D.-J., Lee, M.Y., Jung, I., Moon, S.J., Kwon, H., Park, S.E., Rhee, E.-J., and Lee, W.-Y. (2021). Baseline Homeostasis Model Assessment of Insulin Resistance Associated with Fibrosis Progression in Patients with Nonalcoholic Fatty Liver Disease without Diabetes: A Cohort Study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0255535"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"hcae070.331","DOI":"10.1093\/qjmed\/hcae070.331","article-title":"Serum Ferritin and Cellular Reactive Protein (CRP) in Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH) Patients","volume":"117","author":"Salem","year":"2024","journal-title":"QJM Int. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s40001-024-02065-2","article-title":"High Levels of Serum Hypersensitive C-Reactive Protein Are Associated with Non-Alcoholic Fatty Liver Disease in Non-Obese People: A Cross-Sectional Study","volume":"29","author":"Xia","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, Morbidity and Mortality of Nonalcoholic Fatty Liver Disease","volume":"111","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Todisco, S., Santarsiero, A., Convertini, P., De Stefano, G., Gilio, M., Iacobazzi, V., and Infantino, V. (2022). PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH). Biology, 11.","DOI":"10.3390\/biology11050792"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 Is Crucial for Whole-Body Fatty Acid Homeostasis and Is Protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ye, J.-H., Chao, J., Chang, M.-L., Peng, W.-H., Cheng, H.-Y., Liao, J.-W., and Pao, L.-H. (2016). Pentoxifylline Ameliorates Non-Alcoholic Fatty Liver Disease in Hyperglycaemic and Dyslipidaemic Mice by Upregulating Fatty Acid \u03b2-Oxidation. Sci. Rep., 6.","DOI":"10.1038\/srep33102"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3748\/wjg.v30.i24.3016","article-title":"Alanine Aminotransferase Predicts Incident Steatotic Liver Disease of Metabolic Etiology: Long Life to the Old Biomarker!","volume":"30","author":"Lonardo","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Sogabe, M., Okahisa, T., Kurihara, T., Takehara, M., Kagemoto, K., Okazaki, J., Kida, Y., Hirao, A., Tanaka, H., and Tomonari, T. (2020). Differences among Patients with and without Nonalcoholic Fatty Liver Disease Having Elevated Alanine Aminotransferase Levels at Various Stages of Metabolic Syndrome. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0238388"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12944-023-01811-5","article-title":"Relationship between Triglyceride-Glucose Index and Aminotransferase among Royal Thai Army Personnel 2017\u20132021: A Serial Cross-Sectional Study","volume":"22","author":"Lertsakulbunlue","year":"2023","journal-title":"Lipids Health Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e025524","DOI":"10.1136\/bmjopen-2018-025524","article-title":"Association of Liver Enzymes Levels with Fasting Plasma Glucose Levels in Southern China: A Cross-Sectional Study","volume":"9","author":"Huang","year":"2019","journal-title":"BMJ Open"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1161\/ATVBAHA.112.300075","article-title":"Aminotransferase Levels Are Associated with Cardiometabolic Risk above and beyond Visceral Fat and Insulin Resistance: The Framingham Heart Study","volume":"33","author":"Porter","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_29","unstructured":"(2025, January 26). Diagnosis of NAFLD & NASH\u2014NIDDK, Available online: https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash\/diagnosis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-Invasive Assessment of Non-Alcoholic Fatty Liver Disease: Clinical Prediction Rules and Blood-Based Biomarkers","volume":"68","author":"Chalasani","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Xuan, Y., Wu, D., Zhang, Q., Yu, Z., Yu, J., and Zhou, D. (2024). Elevated ALT\/AST Ratio as a Marker for NAFLD Risk and Severity: Insights from a Cross-Sectional Analysis in the United States. Front. Endocrinol. Lausanne, 15.","DOI":"10.3389\/fendo.2024.1457598"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of Non-Alcoholic and Alcoholic Fatty Liver Diseases","volume":"5","author":"Mitra","year":"2020","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.28390","article-title":"Noninvasive Fatty Liver Markers Predict Liver Disease Mortality in the U.S. Population","volume":"63","author":"Ruhl","year":"2016","journal-title":"Hepatology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cgh.2022.01.046","article-title":"Influence of Nonalcoholic Fatty Liver Disease with Elevated Liver Enzyme Levels on Risk of Cirrhosis and Hepatocellular Carcinoma","volume":"21","author":"Huang","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.atherosclerosis.2008.12.012","article-title":"Elevated Alanine Aminotransferase Levels Predict Mortality from Cardiovascular Disease and Diabetes in Koreans","volume":"205","author":"Yun","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes","volume":"12","author":"Valerio","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of Hepatic Triglyceride Accumulation in Non-Alcoholic Fatty Liver Disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"101092","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated Lipid Metabolism Links NAFLD to Cardiovascular Disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.14401","article-title":"Systematic Review with Meta-Analysis: The Significance of Histological Disease Severity in Lean Patients with Nonalcoholic Fatty Liver Disease","volume":"47","author":"Sookoian","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex Differences in NAFLD: State of the Art and Identification of Research Gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ng, C.H., Wong, Z.Y., Chew, N.W.S., Chan, K.E., Xiao, J., Sayed, N., Lim, W.H., Tan, D.J.H., Loke, R.W.K., and Tay, P.W.L. (2022). Hypertension Is Prevalent in Non-Alcoholic Fatty Liver Disease and Increases All-Cause and Cardiovascular Mortality. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.942753"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and Cardiovascular Diseases: A Clinical Review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e36815","DOI":"10.1097\/MD.0000000000036815","article-title":"The Association between Atherosclerosis and Nonalcoholic Fatty Liver Disease","volume":"103","author":"Lv","year":"2024","journal-title":"Medicine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic Fatty Liver Disease and the Heart","volume":"73","author":"Stahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.18203\/2320-6012.ijrms20201912","article-title":"Relation between non-alcoholic fatty liver disease and ischemic heart disease studied at rural tertiary care centre in Uttar Pradesh, India","volume":"8","author":"Kumar","year":"2020","journal-title":"Int. J. Res. Med. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1177\/0300060518782780","article-title":"Chronic Heart Failure in Patients with Nonalcoholic Fatty Liver Disease: Prevalence, Clinical Features, and Relevance","volume":"46","author":"Zhang","year":"2018","journal-title":"J. Int. Med. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-Alcoholic Fatty Liver Disease-Related Risk of Cardiovascular Disease and Other Cardiac Complications","volume":"24","author":"Byrne","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kim, H., Lee, D.S., An, T.H., Park, H.-J., Kim, W.K., Bae, K.-H., and Oh, K.-J. (2021). Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094495"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/pmj.2005.039032","article-title":"Prevalence of Obesity in Type 2 Diabetes in Secondary Care: Association with Cardiovascular Risk Factors","volume":"82","author":"Daousi","year":"2006","journal-title":"Postgrad. Med. J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Ziolkowska, S., Binienda, A., Jab\u0142kowski, M., Szemraj, J., and Czarny, P. (2021). The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011128"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1161\/ATVBAHA.111.230722","article-title":"Steatosis deLIVERs High Sensitivity C-Reactive Protein","volume":"31","author":"Luyendyk","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12944-024-02031-1","article-title":"What Are the Common Downstream Molecular Events between Alcoholic and Nonalcoholic Fatty Liver?","volume":"23","author":"Tarantino","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Fleming, T.R., and Harrington, D.P. (2005). Weighted Logrank Statistics. Counting Processes and Survival Analysis, John Wiley & Sons, Ltd.","DOI":"10.1002\/9781118150672"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation from Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1214\/aos\/1176344247","article-title":"Nonparametric Inference for a Family of Counting Processes","volume":"6","author":"Aalen","year":"1978","journal-title":"Ann. Stat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The Use of Restricted Mean Survival Time to Estimate the Treatment Effect in Randomized Clinical Trials When the Proportional Hazards Assumption Is in Doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible Parametric Proportional-Hazards and Proportional-Odds Models for Censored Survival Data, with Application to Prognostic Modelling and Estimation of Treatment Effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat. Med."},{"key":"ref_60","unstructured":"StataCorp (2023). Stata Statistical Software: Release 18, StataCorp LLC."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:39:39Z","timestamp":1760031579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/11\/5057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":60,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ijms26115057"],"URL":"https:\/\/doi.org\/10.3390\/ijms26115057","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}